Status: IPO (NASDAQ: AVBP)
ArriVent was founded in 2021 with a mission to globally develop top biopharma innovations from around the world to deliver important medicines to patients. Recognizing the plethora of potential first- and best-in-class candidates out of China and other geographic areas such as Europe, South Korea and Japan, and the risk that these might never make it to market due to development challenges in the areas in which they were discovered, Arrivent has made it their mission to ensure these innovations get into the hands of patients and physicians across the globe.
Their lead clinical asset firmonertinib is built based on a strong understanding of cancer biology and unmet medical need, and they are applying these same skills to other medicines and research collaborations.
ArriVent was listed on NASDAQ in 2024.
To learn more, please visit: www.arrivent.com